Systemic Medications Associated With Hair Texture Changes.
| Autor: | Phong C, Baker G, Esmaeili M, Dobry A, Atanaskova Mesinkovska N |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2022 Sep 01; Vol. 21 (9), pp. 989-996. |
| DOI: | 10.36849/JDD.6852 |
| Abstrakt: | Background: In addition to hair loss, alterations in hair texture can be a worrisome side effect of certain medications yet are seldom reported and poorly characterized. Objective: To systematically analyze the scientific literature to characterize medication-associated hair texture changes. Methods: Relevant primary literature within PubMed and Cochrane was reviewed from 1985-2021 including 31 articles (1 randomized controlled trial with texture changes incidentally noted, 6 cohort, 1 cross-sectional, 23 case studies), comprising 2594 patients. Results: Texture changes were associated primarily with antineoplastic agents (n = 97), antiepileptics (n = 56), retinoids (n = 15), immunomodulators (n = 3), and antiretroviral therapy (n = 1). Average age was 48.4 years old (41.2% female). De novo or exaggerated curling patterns were most commonly reported. Average time to texture change varied from 4.5 months (immunomodulators) to 17 months (antiretrovirals). Prognosis was seldom discussed with reversibility noted across all medication classes (n = 17/21; 3 weeks to 5 years post therapy). Irreversible changes were linked with antiretrovirals, retinoids, and antineoplastics. Limitations: Inability to define true incidence rates, ethnicity, and severity of texture changes due to the nature of available literature. Conclusions: Hair texture changes are potential side effects of antineoplastics, antiepileptics, retinoids, immunomodulators, and antiretroviral therapy. As these can have associated psychosocial impact, awareness among prescribing physicians is important.J Drugs Dermatol. 2022;21(9):989-996 doi:10.36849/JDD.6852. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|